| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In …
Over the last 12 months, insiders at Eloxx Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Eloxx Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Eloxx Pharmaceuticals, Inc. have bought $36,000 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 50,000 shares for transaction amount of $36,000 was made by Geffken Daniel E. (INTERIM CFO) on 2021‑11‑29.
| 2021-11-29 | Geffken Daniel E. | INTERIM CFO | 50,000 0.0579% | $0.72 | $36,000 | -52.78% | ||
| 2021-05-13 | PAREKH RAJESH B | director | 2.47M 2.9505% | $1.35 | $3.33M | -27.06% | ||
| 2021-05-13 | Pontifax Management 4 G.P. (2015) Ltd. | 10 percent owner | 5.93M 7.0883% | $1.35 | $8M | -27.06% | ||
| 2021-05-13 | Nussbaum Ran | director | 5.93M 7.0883% | $1.35 | $8M | -27.06% | ||
| 2021-05-13 | Kariv Tomer | director | 5.93M 7.0883% | $1.35 | $8M | -27.06% | ||
| 2019-06-24 | Pontifax Management 4 G.P. (2015) Ltd. | 10 percent owner | 200,000 0.5562% | $9.00 | $1.8M | -52.66% | ||
| 2019-06-24 | Nussbaum Ran | director | 200,000 0.5562% | $9.00 | $1.8M | -52.66% | ||
| 2019-06-24 | Kariv Tomer | director | 200,000 0.5562% | $9.00 | $1.8M | -52.66% | ||
| 2018-05-22 | Ward Robert | Chief Executive Officer | 5,000 0.0159% | $14.34 | $71,700 | -5.99% | ||
| 2018-04-30 | Shabtai Gilad | 10 percent owner | 75,000 0.1873% | $9.75 | $731,250 | +10.18% | ||
| 2018-04-30 | Kleijwegt Martijn | director | 300,000 0.7491% | $9.75 | $2.92M | +10.18% | ||
| 2018-04-30 | Pontifax Management 4 G.P. (2015) Ltd. | 10 percent owner | 350,000 0.8739% | $9.75 | $3.41M | +10.18% | ||
| 2018-04-30 | Nussbaum Ran | director | 350,000 0.8739% | $9.75 | $3.41M | +10.18% | ||
| 2018-04-30 | Kariv Tomer | director | 350,000 0.8739% | $9.75 | $3.41M | +10.18% | ||
| 2018-04-04 | Shabtai Gilad | 10 percent owner | 2,600 0.0081% | $9.58 | $24,908 | +39.43% | ||
| 2018-04-03 | Shabtai Gilad | 10 percent owner | 5,700 0.0176% | $9.41 | $53,637 | +40.89% | ||
| 2018-03-29 | Shabtai Gilad | 10 percent owner | 4,500 0.0164% | $9.64 | $43,380 | +40.89% | ||
| 2018-03-26 | Avnur Zafrira | director | 2,000 0.0079% | $9.49 | $18,980 | +55.46% | ||
| 2018-03-23 | Ward Robert | Chief Executive Officer | 10,000 0.0363% | $8.99 | $89,900 | +51.11% | ||
| 2018-03-23 | WEAVER GREGORY L | Chief Financial Officer | 4,500 0.0156% | $8.56 | $38,520 | +51.11% |
| FORBES CHRISTOPHER | 12757318 371.2501% | $164.82M | 40 | 0 | ||
| PAREKH RAJESH B | director | 4827129 140.474% | $62.37M | 1 | 0 | <0.0001% |
| Kariv Tomer | director | 3679797 107.0856% | $47.54M | 5 | 0 | +13.64% |
| Nussbaum Ran | director | 3679797 107.0856% | $47.54M | 5 | 0 | +13.64% |
| Pontifax Management 4 G.P. (2015) Ltd. | 10 percent owner | 3679797 107.0856% | $47.54M | 5 | 0 | +13.64% |
| Shabtai Gilad | 10 percent owner | 3351770 97.5397% | $43.3M | 4 | 0 | +32.85% |
| Kleijwegt Martijn | director | 2953673 85.9547% | $38.16M | 1 | 0 | +10.18% |
| Waksal Harlan | director | 1902590 55.3672% | $24.58M | 3 | 0 | |
| FROST PHILLIP MD ET AL | 1598170 46.5083% | $20.65M | 1 | 0 | ||
| QUICK THOMAS C | director | 480120 13.9719% | $6.2M | 2 | 0 | |
| STALDER RUEDI | director | 382549 11.1325% | $4.94M | 6 | 0 | |
| RECTOR DAVID | director | 352785 10.2664% | $4.56M | 13 | 0 | |
| BROOKS JOEL | CFO and Treasurer | 102275 2.9763% | $1.32M | 1 | 2 | |
| GALTON BRUCE C | 98450 2.865% | $1.27M | 2 | 10 | ||
| BRACA JOHN N | director | 55167 1.6054% | $712,757.64 | 8 | 0 | |
| Geffken Daniel E. | INTERIM CFO | 50000 1.455% | $646,000.00 | 1 | 0 | <0.0001% |
| Van Hulst Jack | President and CEO | 22659 0.6594% | $292,754.28 | 2 | 0 | |
| Isabelle Warren John | director | 18967 0.552% | $245,053.64 | 2 | 0 | |
| Ward Robert | Chief Executive Officer | 15000 0.4365% | $193,800.00 | 2 | 0 | +22.56% |
| WEAVER GREGORY L | Chief Financial Officer | 4500 0.131% | $58,140.00 | 1 | 0 | +51.11% |
| Avnur Zafrira | director | 2263 0.0659% | $29,237.96 | 2 | 0 | +63.88% |
| Browne Leslie J | President and CEO | 1290 0.0375% | $16,666.80 | 6 | 0 |
$2,542,362 | 111 | 11.81% | $36.83M | |
$156,891,025 | 80 | -24.91% | $36.3M | |
$84,911,583 | 59 | 17.82% | $37.44M | |
$693,326 | 47 | -16.24% | $40.24M | |
$6,204,522 | 45 | 1.91% | $36.5M |
| Increased Positions | 0 | 0% | 0 | 0% |
| Decreased Positions | 0 | 0% | 0 | 0% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 0 | 0% | 0 | 0% |